|Day Low/High||74.81 / 75.47|
|52 Wk Low/High||73.21 / 94.19|
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.
Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.
Here's what you need to know now for Friday, May 18.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
Last week, the Swiss drug giant's $1.2 million in payments to President Trump's fixer Michael Cohen became public. Now the government of Switzerland as well as two U.S. senators are looking into them.
U.S. stock futures are slightly higher Friday as Wall Street prepares for the Trump administration's North Korea summit and China trade talks. AT&T and Novartis pick up the pieces. JPMorgan overhauls stock trading.
Pharma giant Novartis is now immersed in the muck that is the Trump-Russia probe thanks to $1.2 million in payments to a shell company created by President Trump's fixer Michael Cohen.
U.S. stock futures are higher Wednesday morning as Wall Street digests President Trump's decision to exit the Iran deal. Disney beat on the top and bottom line, while Facebook is making major changes to its executive leadership.
The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.
The drugmakers and health insurer are preparing to unveil first-quarter numbers.
The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.
Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.
Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
Jim Cramer says we're seeing powerful reminders that there's a better time to sell than in the teeth of a decline. Investors must use discipline to their advantage.
Here's what you need to know for Monday, April 9.
Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
A look at possible second-quarter M&A activity in the biotech sector.
Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.
Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.
U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.